# US 2022/0031641 A1 · Compositions and methods for treating and preventing cognitive dysfunction

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0031641 A1
- Document ID: US20220031641A1
- Status: Published application
- Kind: A1
- Application number: 17/382,045
- Filed: 2021-07-21
- Published: 2022-02-03
- Earliest claimed: 2019-01-24
- Assignees: PharmatrophiX, Inc.; The Board of Trustees of the Leland Stanford Junior University
- Applicants: Pharmatrophix, Inc.; The Board and Trustees of the Leland Stanford Junior University
- Inventors: Michelle Leigh Monje-Deisseroth; Frank M. Longo
- Web page: https://patentgrep.com/patent/US20220031641A1

## CPC

- A61K 31/166: having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Provided are compositions and methods comprising agonists. Also disclosed are agonist compounds, pharmaceutical compositions of agonists, and methods of using the same.

## Claims

### Claim at position 1

1-45. (canceled)

### Claim 46

A method of preventing or treating a cancer therapeutic-related cognitive dysfunction, comprising administering to a subject in need thereof an effective amount of a TrkB agonist, wherein said TrkB agonist is administered to the subject before, during, or after completion of the administration of a cancer treatment regimen or a combination thereof.

### Claim 47 (depends on 46)

The method of claim 46, wherein the cancer treatment regimen comprises one or more doses of chemotherapy, one or more doses of radiation therapy, or one or more doses of immunomodulatory therapy.

### Claim 48 (depends on 46)

The method of claim 46, wherein the method further comprises administering to the subject a test of cognitive function prior to administration of the TrkB agonist.

### Claim 49 (depends on 48)

The method of claim 48, wherein the test of cognitive function indicates that the subject has a cognitive dysfunction.

### Claim 50 (depends on 48)

The method of claim 48, wherein the test of cognitive function is selected from the General Practitioner Assessment of Cognition (GPCOG), Memory Impairment Screen (MIS), MiniMental State Exam (MMSE), and the Six Item Cognitive Impairment Test (6CIT).

### Claim 51 (depends on 46)

The method of claim 46, wherein the cognitive dysfunction comprises one or more symptoms selected from: being unusually disorganized, confusion, difficulty concentrating, difficulty finding the right word, difficulty learning new skills, difficulty multitasking, fatigue, feeling of mental fogginess, short attention span, short-term memory problems, taking longer than usual to complete routine tasks, trouble with verbal memory, adynamia, lack of motivation, impulsiveness, disinhibition, verbosity, tangentiality, irritability, fidgety, low frustration tolerance and trouble with visual memory.

### Claim 52 (depends on 46)

The method of claim 46, wherein the method further comprises administering a test of cognitive function after administration of an effective amount of the TrkB agonist.

### Claim 53 (depends on 52)

The method of claim 52, wherein the test of cognitive function after administration of an effective amount of the TrkB agonist indicates maintenance or improvement in cognitive function of the subject, or improvement in one or more symptoms of cognitive dysfunction of the subject.

### Claim 54 (depends on 46)

The method of claim 46, wherein said method comprises administering said TrkB agonist to the subject after completion of the administration of the cancer treatment regimen.

### Claim 55 (depends on 54)

The method of claim 54, wherein said method comprises administering said TrkB agonist to the subject for about 1 month to about 2 years after completion of the administration of the cancer treatment regimen.

### Claim 56 (depends on 46)

The method of claim 46, wherein said method comprises administering said TrkB agonist to the subject before the administration of the cancer treatment regimen.

### Claim 57 (depends on 46)

The method of claim 46, wherein the method comprises administering said TrkB agonist to the subject during the cancer treatment regimen.

### Claim 58 (depends on 57)

The method of claim 57, wherein the TrkB agonist is administered to the subject within six hours of administration of a dose of the cancer treatment regimen.

### Claim 59 (depends on 46)

The method of claim 46, wherein the TrkB agonist is administered daily, every other day, every third day, or every fourth day.

### Claim 60 (depends on 46)

The method of claim 46, wherein the method comprises promoting or maintaining growth of glial cells.

### Claim 61 (depends on 46)

The method of claim 46, wherein the subject has a cancer selected from breast cancer, ovarian cancer, prostate cancer, leukemia, lymphoma, brain tumor, and sarcoma.

### Claim 62 (depends on 46)

The method of claim 46, wherein the subject has a cancer selected from a cancer of the central nervous system.

### Claim 63 (depends on 46)

The method of claim 46, wherein the TrkB agonist is selected from: N-Acetylserotonin, Amitriptyline, BNN-20, BNN-27, Brain-derived neurotrophic factor, Deoxygedunin, 7,8-Dihydroxyflavone, 4′-Dimethylamino-7,8-dihydroxyflavone, Diosmetin, HIOC, LM22A-4, LM22B-10, Neurotrophin-3, Neurotrophin-4, Norwogonin, R7, R13, and 7,8,3′-Trihydroxyflavone.

### Claim 64 (depends on 46)

The method of claim 46, wherein the TrkB agonist is a small molecule mimetic of a brain-derived neurotrophic factor (BDNF) β-turn loop, wherein the β-turn loop is loop 2, and the small molecule mimetic has a structure of Formula (II):
or a pharmaceutically acceptable salt thereof, wherein:
L1 and L3 are independently selected from the group consisting of C1-C5 alkylene, arylene, aralkylene, and substituted arylene;
L2 is selected from the group consisting of C1-C5 alkylene, arylene, aralkylene, substituted arylene,
L4 is C1-C5 alkylene;
Z1, Z2, and Z3 are independently selected from the group consisting of H, alkyl, aryl, and aralkyl;
X3, X4, X5, and X6 are independently N or CH;
Y1, Y2, and Y3 are independently carbonyl, sulfonyl, or methylene; and
D2, D3, D4, and D5 are independently selected from H, alkyl, halo, hydroxyl, mercapto, mercaptoalkyl, alkoxyl, aryloxyl, aralkoxyl, acyloxyl, carboxyl, alkyloxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, acylamino, carbamoyl, alkylcarbamoyl, dialkylcarbamoyl,
wherein R5, R6, R7, R8, and R9 are independently selected from H, alkyl, aralkyl, and aryl.

### Claim 65 (depends on 64)

The method of claim 64, wherein the compound is selected from the group consisting of:
and a pharmaceutically acceptable salt of any one thereof.
